Market Place
Sourcing Support
TILT Presents TILT-123 IV Delivery Data At ESMO 2024
09 Sep 2024 //
GLOBENEWSWIRE
TILT Bio: TILT-123 Ovarian Cancer Data Presented At ASCO 2024
28 May 2024 //
GLOBENEWSWIRE
TILT Biotherapeutics Presents TILT-123 Data with KEYTRUDA®
10 Apr 2024 //
GLOBENEWSWIRE
TILT Bio Awarded USD 2M Grant for Ovarian Cancer Immunotherapy Research
14 Feb 2024 //
GLOBENEWSWIRE
TILT Announces Data in Checkpoint Resistant Metastatic Melanoma Ph I Trial
08 Dec 2023 //
GLOBENEWSWIRE
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123
06 Nov 2023 //
GLOBENEWSWIRE
TILT Biotherapeutics Announces First Patient Dosed in Ph I Solid Tumors Trial
15 May 2023 //
GLOBENEWSWIRE
First patient dosed in TILT-123 Phase I trial
15 May 2023 //
CLINICAL TRIALS ARENA
Aldeyra Therapeutics Announces FDA Acceptance of NDA for Reproxalap
07 Feb 2023 //
BUSINESSWIRE
TILT Announces Boston Office Opening as it Expands its Trials in the US
09 Nov 2022 //
BUSINESSWIRE
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Trial
11 Oct 2022 //
PHARMIWEB
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial
26 Sep 2022 //
BUSINESSWIRE
TILT Bio Announces Positive Update on its Phase 1 Immunotherapy Trials
30 Mar 2022 //
BUSINESSWIRE
TILT Bio Announces Data at ESMO on Its Oncolytic Immunotherapy Platform
17 Sep 2021 //
BIOSPACE
TILT Reports Publication on its Oncolytic Immunotherapy Platform
27 Aug 2021 //
PHARMIWEB
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123
14 Jun 2021 //
BUSINESSWIRE
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123
14 Jun 2021 //
BUSINESSWIRE
TILT Biotherapeutics and MSD to Collaborate on Trial of Adenoviral Cancer
14 Apr 2021 //
BUSINESSWIRE
TILT and MSD to Collaborate on Clinical Trial of Adenoviral TILT-123
14 Apr 2021 //
BUSINESSWIRE
TILT Biotherapeutics & MSD to collaborate on adenoviral cancer trial
14 Apr 2021 //
PHARMFILE
TILT advances cancer immunotherapy clinical trial achieving primary end point
15 Mar 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.